Cellular Intelligence, a burgeoning biotech startup, has announced the acquisition of global rights to a clinical-stage Parkinson’s disease cell therapy,…
Read More
Engineered exosomes from pig semen: a high-yield platform for non-invasive ocular drug delivery
In a remarkable breakthrough in ocular pharmacology, researchers in China have pioneered the development of novel eye drops derived from…
Read More
The New York Times spotlighted MEDVi. The FDA had already warned the self-proclaimed ‘fastest growing company in history.’
The narrative of MEDVi, an AI-powered telehealth startup, recently unfolded with a stark duality: hailed by The New York Times…
Read More
How to tackle the unique pharmacokinetic properties of covalent drugs
The landscape of modern therapeutics has been significantly shaped by covalent drugs, a class of pharmaceuticals distinguished by their ability…
Read More
Sai Life Sciences’ Biotech Pitch Day 2026 Ignites Innovation with Promising Early-Stage Biotech Ventures
Sai Life Sciences, a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), recently convened its highly anticipated Biotech Pitch…
Read More
Pharma 50: Keytruda holds the top brand slot, but tirzepatide and semaglutide have already passed it at the molecule level in FY2025
Merck’s immunotherapy blockbuster, Keytruda (pembrolizumab), maintained its dominant position as the pharmaceutical industry’s leading brand in Fiscal Year 2025, recording…
Read More
Pharma 50: The 50 best-selling drugs of FY2025
The pharmaceutical landscape of Fiscal Year 2025 witnessed a dynamic reshuffling at its apex, with Merck’s Keytruda steadfastly holding its…
Read More
Beyond the silver bullet: Why precision medicine is the next frontier for the $1 trillion obesity market
The burgeoning global market for obesity treatments, propelled past the $1 trillion valuation by the meteoric rise of GLP-1 receptor…
Read More
Rethinking evidence generation for ultra-rare diseases
The landscape of drug development for ultra-rare diseases is undergoing a significant transformation, driven by the inherent limitations of traditional…
Read More
Medvi: The $1.8 Billion Telehealth Company Built on Regulatory Gaps, Fake Testimonials, and AI Deception
A recent profile by The New York Times lauded Medvi as a prime example of artificial intelligence’s potential to empower…
Read More
